Compare Moderna, Inc. (MRNA) vs Okta, Inc. (OKTA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Okta, Inc. — how do they compare? Moderna, Inc. trades at $218.64 (market cap $78.65B), while Okta, Inc. trades at $227.72 (market cap $38.50B). The key difference: Moderna, Inc. is far larger — about 2× Okta, Inc.'s market cap, and Moderna, Inc. is more actively traded (37,373,437 versus 2,479,621). Which is the better fit depends on your goals — on Pluang, investors hold Moderna, Inc. for 59 Days and Okta, Inc. for 44 Days on average.
| MRNA | OKTA | |
|---|---|---|
Market Cap | $78.65B | $38.50B |
Volume | 37,373,437 | 2,479,621 |
Sector | Health | Technology |
52-Week High | $203.46 | $220.21 |
52-Week Low | $22.36 | $62.93 |
Typical Hold Time | 59 Days | 44 Days |
Enterprise Value | $74.80B | $36.25B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $214.50, up 9.17% with strong technical momentum. The stock shows bullish moving average signals despite negative profitability metrics, with revenue declining from $18.9B in 2022 to $1.92B in 2025. Recent Nasdaq-100 inclusion creates institutional demand, though Citigroup downgraded to Sell citing valuation concerns after a 500% 2026 rally. The company continues beating EPS expectations despite net losses.
Outlook remains bifurcated between technical strength and fundamental challenges. The cancer vaccine pipeline offers growth potential, but persistent losses and high valuations create headwinds. Near-term momentum may continue from index fund inflows, though profitability concerns warrant caution for long-term investors.
Okta's stock trades at $228.38, up 4.76% in the last 24 hours, reflecting strong momentum. The company has beaten earnings estimates for three consecutive quarters, with Q3 2026 results pending. Revenue growth is robust, rising from $1.3B in 2022 to $2.6B in 2025, and profitability has improved significantly, turning a net loss into a $28M profit. Technical indicators show a bullish trend, with the current price near resistance at $228. Recent news highlights Okta's strategic focus on AI agent security, positioning it for future growth in the cybersecurity sector.
The outlook for Okta is positive, driven by strong earnings performance, revenue expansion, and strategic initiatives in AI. However, risks include high valuation multiples, such as a P/E of 132.66, and competitive pressures in the cybersecurity space. Analyst consensus is overwhelmingly bullish, with 73.58% recommending Buy, but investors should monitor execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Okta, Inc.
Okta is a cloud-native security company that focuses on identity and access management. The San Francisco-based firm went public in 2017 and focuses on two key client stakeholder groups: workforces and customers. Okta's workforce offerings enable a company's employees to securely access its cloud-based and on-premises resources. The firm's customer offerings allow its clients' customers to securely access the client's applications.
Read more on OKTA →
